AU1991901A - Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof - Google Patents

Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof

Info

Publication number
AU1991901A
AU1991901A AU19919/01A AU1991901A AU1991901A AU 1991901 A AU1991901 A AU 1991901A AU 19919/01 A AU19919/01 A AU 19919/01A AU 1991901 A AU1991901 A AU 1991901A AU 1991901 A AU1991901 A AU 1991901A
Authority
AU
Australia
Prior art keywords
cea
express
treating
pharmaceutical composition
human tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19919/01A
Inventor
Gabriele Pecher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1991901A publication Critical patent/AU1991901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU19919/01A 1999-09-27 2000-09-26 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof Abandoned AU1991901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19948105 1999-09-27
DE19948105 1999-09-27
PCT/DE2000/003443 WO2001024832A2 (en) 1999-09-27 2000-09-26 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof

Publications (1)

Publication Number Publication Date
AU1991901A true AU1991901A (en) 2001-05-10

Family

ID=7924664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19919/01A Abandoned AU1991901A (en) 1999-09-27 2000-09-26 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof

Country Status (4)

Country Link
EP (1) EP1409534A2 (en)
AU (1) AU1991901A (en)
DE (1) DE10048710A1 (en)
WO (1) WO2001024832A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
CA2545164C (en) 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
JP5285855B2 (en) * 2003-11-12 2013-09-11 アメリカ合衆国 Custom vectors for treating and preventing pancreatic cancer
EP1716173B8 (en) 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Carcinoembryonic antigen fusion protein and uses thereof
CN101616693A (en) 2006-11-24 2009-12-30 泰根尼克斯股份有限公司 Be used to identify that chondrocyte phenotypic stability and screening cartilage form the marker gene of factor of influence
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197765T1 (en) * 1994-10-03 2000-12-15 Us Gov Health & Human Serv COMPOSITION CONTAINING AN ANTIGEN-EXPRESSING RECOMBINANT VIRUS AND AN IMMUNO-STIMULATING MOLECULE-EXPRESSING RECOMBINANT VIRUS
DE19516673A1 (en) * 1995-04-28 1996-10-31 Gabriele Dr Pecher Vaccines against human, pref. mucin expressing, tumours
DE19617837A1 (en) * 1996-04-19 1997-10-23 Gabriele Dr Pecher Anticancer vaccine containing human dendritic cells
EP0906444A1 (en) * 1996-04-19 1999-04-07 Gabriele Pecher Genetically transfected human dendritic cells, their production and use, preferably as vaccines
DE69936061T2 (en) * 1998-12-09 2008-01-17 Therion Biologics Corp., Cambridge RECOMBINANT VECTOR, EXPRESSING AND USING SEVERAL COSTIMULATORY MOLECULES

Also Published As

Publication number Publication date
WO2001024832A2 (en) 2001-04-12
EP1409534A2 (en) 2004-04-21
DE10048710A1 (en) 2001-10-04
WO2001024832A3 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
PL354540A1 (en) Drugs for the treatment of malignant tumours
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
AU4373499A (en) Use of drug-loaded nanoparticles for the treatment of cancers
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
PL355172A1 (en) Oncolytic combinations for the treatment of cancer
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
MXPA02004942A (en) Use of anti idiotypical antibodies as vaccines against cancer.
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2390700A (en) Polypeptidic compositions and methods for the treatment of tumors
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 29, PAGE(S) 6074-6077 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 70161/00, 76674/00, 16911/01 AND 19919/01

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase